GlassScriptPhysician profile
Mckenzie Lee Webster
NPI 1376233353
$1,143.18
in general payments reported to CMS, 2019-2025
19 companies · $883 in 2025
The $883 reported for 2025 was more than what 88% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $260 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,143.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $211.25 | 2025 | Veozah |
| Novo Nordisk INC | $154.36 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Viiv Healthcare Company | $134.83 | 2025 | Apretude, Cabenuva |
| Pfizer INC. | $102.29 | 2024-2025 | |
| Gilead Sciences, INC. | $93.67 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $83.22 | 2024-2025 | Farxiga |
| Abbvie INC. | $70.60 | 2025 | |
| Sanofi-Aventis U.S. LLC | $45.15 | 2024-2025 | |
| Exact Sciences Corporation | $39.48 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amgen INC. | $36.02 | 2024-2025 | Evenity, Prolia |
| Lilly USA, LLC | $31.03 | 2025 | Jardiance |
| Esperion Therapeutics, INC. | $21.52 | 2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $21.43 | 2025 | |
| Hologic Sales and Service, LLC | $20.42 | 2025 | Thinprep 2000 Processor, Aptima |
| Takeda Pharmaceuticals U.S.A., INC. | $17.84 | 2025 | Trintellix |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vital Connect, INC | $15.94 | 2024 | Vitalpatch Rtm |
| Dexcom, INC. | $15.64 | 2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.71 | 2024 | Xifaxan |
| Supernus Pharmaceuticals, INC. | $13.78 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mckenzie Webster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.